JASIM ADIL KAREEM1, MOHAMED JAWAD LAITH ABDUL HASSAN2*
1Department of Biology, College of Science, Al-Muthanna University 550, Samawa, Iraq
2Department of Biology, College of Science, Al-Muthanna University 550, Samawa, Iraq
* Corresponding Author : atabdlih@mu.edu.iq
Received : 11-02-2018 Accepted : 14-03-2018 Published : 30-03-2018
Volume : 10 Issue : 3 Pages : 1070 - 1073
Int J Microbiol Res 10.3 (2018):1070-1073
DOI : http://dx.doi.org/10.9735/0975-5276.10.3.1070-1073
Keywords : Rotavirus, sequencing, phylogenetic analyses, viral genes
Academic Editor : Mohamad Qasim Whaieb, Nihad A. Al-Rashedi
Conflict of Interest : None declared
Acknowledgements/Funding : Author thankful to Al-Muthanna University 550, Samawa, Iraq
Author Contribution : All author equally contributed
Group A rotavirus leftovers a main reason of diarrhea in infants and young children particularly in developing countries. Nursing changes in rotavirus strains is essential to measure the possible effectiveness of vaccines in exact geographic sites. Stool samples were collected from children below 2 years suffering after severe diarrhea. Positive samples were amplified to examine and characterized VP4 gene. The greatest predominant genotype was G1P[8] (6/13)(46.15) followed by G3P[8] (2/13)(15.38), G2P[6] (1/13)(7.69), G4P[8] (1/13)(7.69), G9P[8] (1/13)(7,69). A phylogenetic analysis and sequencing identity matrix to VP4 gene of isolates detected in the present study exposed that G1P8 (Iq4-f2,Iq4-f5, Iq4-f7, Iq4-f6, Iq4-f4) in lineage 1 of phylogenetic tree, similarity between those isolates 100%. G1P8 (Iq4-s3) and G4P8 (Iq4-f1) of lineage 1 similarity between these isolates (94%), and isolates Iq4-s3 and Iq4-f1 identity (93-94%) to next isolates (Iq4-f2, Iq4-f5, Iq4-f7, Iq4-f6, Iq4-f4). Two isolates (Ig4-f8, Ig4-f9) in lineage 2 was similar (99%). Vaccine isolate of vp4 gene (lineage 1) similarity (89%) to G4P8 (Iq4-f1), (88%) to G1P8 (Iq4-f2, Iq4-f4, Iq4-f5, Iq4-f6, Iq4-f7). The distribution of genotypes that own neither VP4 specificity through the obtainable rotavirus vaccine presently in use may embody a challenge to the consequence and accomplishment of vaccination.
1. Kosek M., Bern C. and Guerrant R. (2003) Bull World Health Organ, 81, 197–204.
2. Lee R.M., Lessler J. and Lee R.A. (2013) BMC Infectious Diseases, 13, 446.
3. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A. and Glass R.I (2003) Emerg Infect Dis, 9, 565–572.
4. Estes M.K. and Greenberg H.B. (2013) Rotaviruses. In: Fields Virology. 6th Edn, Williams and Wilkins.
5. Diggle L. (2007) Br J Nurs, 16, 970–974.
6. Matthijnssens J., Ciarlet M. and McDonald S.M. (2011) Arch Virol, 156, 1397–1413.
7. Dennehy P.H. (2008) Clinical Microbiology Reviews, 2, 198-208.
8. Leshem E., Lopman B. and Glass R. (2014) Lancet Infect Dis, 14, 847–856.
9. Ahmed M.H., Coulter S.B., NaKagomi O., Hart C.A. and Zaki J.M. (2006) Emerg infect. Dis, 12, 824-926.
10. Simmonds M.K., Armah G. and Asmah R. (2008) J Clin Virol, 42, 368–733.
11. Woolley S.M., Posada D. and Crandall K.A. (2008) PLoS One, 3, 13-19.
12. Bonkoungou I.J., Damanka S. and Sanou I. (2011) J Med Virol, 83, 1485–1490.